[Helicobacter pylori eradication therapy in children]

Area of Science:

• Pediatric Gastroenterology
• Infectious Diseases
• Microbiology

Background:

• Helicobacter pylori (H. pylori) eradication is recommended for Japanese children with peptic ulcer disease or refractory iron deficiency anemia.
• First-line triple therapy (PPI+amoxicillin+clarithromycin) shows declining efficacy, with eradication rates around 70% due to high clarithromycin resistance (over 40%) in Japanese children.
• Antibiotic susceptibility testing is becoming a consideration for guiding first-line H. pylori eradication therapies.

Purpose of the Study:

• To review current recommendations and challenges in H. pylori eradication therapy for Japanese children.
• To highlight the impact of increasing clarithromycin resistance on treatment efficacy.
• To discuss the role of antibiotic susceptibility testing and potential alternative therapies.

Main Methods:

• Literature review of H. pylori eradication strategies in pediatric populations, with a focus on Japanese data.
• Analysis of reported eradication rates for standard and alternative therapies.
• Examination of antibiotic resistance patterns, particularly for clarithromycin.

Main Results:

• First-line triple therapy (PPI+amoxicillin+clarithromycin) has a decreasing eradication rate of approximately 70% in Japanese children.
• Clarithromycin resistance rates exceed 40%, significantly impacting treatment success.
• Triple therapy with PPI+amoxicillin+metronidazole is a viable second-line option.

Conclusions:

• Effective H. pylori eradication in Japanese children necessitates addressing high clarithromycin resistance.
• Consideration of antibiotic susceptibility testing prior to initiating therapy is warranted.
• Further research into sequential therapy options for this population is needed, as data is currently lacking.